Clinical trial
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative…
NCT00129389 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00129389 |
|---|---|
| Title | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients |
| Official title | Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Fluorouracil, Doxorubicin, Cyclophosphamide, Paclitaxel |
| Enrollment | 1,925 |
| Start date | Sep 19, 2003 |
| Primary completion | Oct 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Aug 11, 2005 |
| Last update posted | Mar 7, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: